Skip to main content
SpringerLink
Log in

Actualités dans le myélome multiple

Advances in multiple myeloma

  • Synthèse / Review Article
  • Published:
Oncologie

Abstract

This article reviews recent publications and takes stock of the current situation in the treatment of myeloma.

Résumé

S’appuyant sur de récentes publications, cet article propose un point concernant la prise en charge thérapeutique des patients porteurs de myélome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Attal M, Cances Lauwers V, Marit G, et al. (2010) Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02. Blood (ASH Annual Meeting Abstracts) 116: 310

    Google Scholar 

  2. Cavo M, Tacchetti P, Patriarca F, et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction treatment before, and consolidation therapy after double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 376: 2075–2085

    Article  PubMed  CAS  Google Scholar 

  3. Fayers PM, Palumbo A, Hulin C, et al. (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1,685 individual patient data from six randomized clinical trials. Blood 118: 1234–1247

    Article  Google Scholar 

  4. Jakubowiak AJ, Siegel DS, Vij R, et al (2011) The emerging role of second generation proteasome inhibitors, including carfilzomib and other agents: clinical data. Haematologica 96: (s1) 13th International Myeloma Workshop, Paris, France

  5. Lacy MQ, Hayman SR, Gertz MA, et al. (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 27: 5008–5014

    Article  PubMed  CAS  Google Scholar 

  6. Lacy MQ, Hayman SR, Gertz MA, et al (2010) Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24: 1934–1939

    Article  PubMed  CAS  Google Scholar 

  7. Lonial S, Jagannath S (2011) Monoclonal antibodies in the treatment of multiple myeloma. Haematologica 96: (s1) 13th International Myeloma Workshop, Paris, France

  8. Mateos MV, Oriol A, Martínez-López J, et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11: 934–941

    Article  PubMed  CAS  Google Scholar 

  9. Mateos MV, Richardson PG, Schlag R, et al. (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28: 2259–2266

    Article  PubMed  CAS  Google Scholar 

  10. Moreau P, Facon T, Attal M, et al (2010) Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): results of IFM2007-02 study. ASCO Annual Meeting Proceedings. J Clin Oncol 28(15 Suppl): 8014 (May 20 Supplement)

    Google Scholar 

  11. Moreau P, Pylypenko H, Grosicki S, et al. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12: 431–440

    Article  PubMed  Google Scholar 

  12. Ocio EM, Vilanova D, Atadja P, et al (2010) In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 95: 794–803

    Article  PubMed  CAS  Google Scholar 

  13. Palumbo A, Bringhen S, Rossi D, et al. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28: 5101–5109

    Article  PubMed  CAS  Google Scholar 

  14. Richardson P, Weller E, Lonial S, et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679–686

    Article  PubMed  CAS  Google Scholar 

  15. Richardson PGG, Moreau P, Jakubowiak AJ, et al. (2011) Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study. 2011 ASCO Annual Meeting. J Clin Oncol 29: (Suppl; abstr 8014)

  16. Rosiñol L, Cibeira MT, Mateos MV, et al (2010) A phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In multiple myeloma: superiority of VTD bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib. Blood (ASH Annual Meeting Abstracts) 116: 307

    Google Scholar 

  17. Roussel M, Avet-Loiseau H, Moreau P, et al. (2010) Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 Phase II Study. Blood (ASH Annual Meeting Abstracts) 116: 624

    Google Scholar 

  18. Sonneveld P, Schmidt-Wolf I, van der Holt B, et al (2010) HOVON-65/GMMGHD4 randomized phase III Trial Comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 116: 40

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie clinique, centre hospitalier universitaire de Nantes Hôtel-Dieu, 1, place Alexis-Ricordeau, F-44093, Nantes, France

    P. Moreau

Authors
  1. P. Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Moreau.

About this article

Cite this article

Moreau, P. Actualités dans le myélome multiple. Oncologie 13, 548–552 (2011). https://doi.org/10.1007/s10269-011-2071-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-011-2071-3

Keywords

Mots clés

Search

Navigation